Form D · Biotechnology

BIOTRICITY INC.

Redwood City, CA · CIK 0001630113

Offering snapshot reported Apr 9, 2024 · SEC filing

Reported sold
$1M
Offering amount: $1M
Investors reported
1
Form D · investor count
Minimum accepted
$1M
Reported outside-investor minimum
First sale
Mar 25, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 9, 2024Initial$1,000,000No comparison1SEC filing
Aug 10, 2020Initial$1,253,000No comparison24SEC filing
Dec 31, 2019Initial$6,000,000No comparison1SEC filing
Mar 17, 2017Initial$1,232,000No comparison0SEC filing
Aug 5, 2016Amendment$1,150,000$625,000vs Apr 18, 20164SEC filing
Apr 18, 2016Initial$525,000No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-510115

Source: Form D, filed Apr 9, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Waqaas Al Siddiq Director, Executive
John Ayanoglou Executive
Norman Betts Director
Norman M. Betts, M.D. Director
Patricia Kennedy Director
Ronald Mc Clurg Director
David A. Rosa Director
Steve Salmon Director
Chester White Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
203 Redwood Shores Parkway Suite 600
Redwood City, CA, 94065